Changes at the FDA have altered the device approval landscape, with the de novo route now the most popular.
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Pipeline projects are forecast to contribute a substantial proportion of future sales at Abbvie and Lilly, though the same cannot be said for all big drug developers.